India has introduced Janssen's Sirturo (bedaquiline), a poster child in the war against multidrug-resistant tuberculosis (MDR-TB), through its Revised National Tuberculosis Control Program (RNTCP).
Janssen, on March 22, said that it has donated 600 courses of Sirturo to the RNTCP for use as part of a conditional access program – about the same number of patients will get free access to the drug through six public hospitals and institutes of national importance